Phaseline

Companies › Shanghai Escugen Biotechnology

Shanghai Escugen Biotechnology: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 2 Phase 1; Hematology, Oncology; next expected readout Apr 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
ESG206–Phase 1Immune Thrombocytopenia (ITP)Apr 2027
ESG406–Phase 1Locally Advanced/Metastatic Solid TumorsApr 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06853444ESG206Phase 1Immune Thrombocytopenia (ITP)HematologyApr 2027
NCT06979674ESG406Phase 1Locally Advanced/Metastatic Solid TumorsOncologyApr 2028

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.